

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
28 April 2005 (28.04.2005)

PCT

(10) International Publication Number
WO 2005/037812 A1

(51) International Patent Classification⁷: **C07D 307/68,**
A61K 31/341, A61P 29/00

(21) International Application Number:
PCT/GB2004/004392

(22) International Filing Date: 15 October 2004 (15.10.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0324269.0 16 October 2003 (16.10.2003) GB
60/512,200 20 October 2003 (20.10.2003) US

(71) Applicant (for all designated States except US): **PHARMAGENE LABORATORIES LIMITED** [GB/GB]; 2 Orchard Road, Royston Hertfordshire SG8 5HD (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CLARK, David,** Edward [GB/GB]; c/o Argenta Discovery Limited, 8/9 Spire Green Centre, Flex Meadow, Harlow ESSEX CM19 5TR (GB). **HARRIS, Neil,** Victor [GB/GB]; c/o Argenta Discovery Limited, 8/9 Spire Green Centre, Flex Meadow, Harlow Essex CM19 5TR (GB). **FENTON, Garry** [GB/GB]; c/o Argenta Discovery Limited, 8/9 Spire Green Centre, Flex Meadow, Harlow Essex CM19 5TR (GB). **HYND, George** [GB/GB]; c/o Argenta Discovery Limited, 8/9 Spire Green Centre, Flex Meadow, Harlow Essex CM19 5TR (GB). **STUTTLE, Keith,** Alfred, James [GB/GB]; c/o Argenta Discovery Limited, 8/9 Spire Green Centre, Flex Meadow, Harlow Essex CM19 5TR (GB). **SUTTON, Jonathan,** Mark [GB/GB]; c/o Argenta Discovery Limited, 8/9 Spire Green Centre, Flex Meadow, Harlow Essex CM19 5TR (GB). **OXFORD, Alexander,** William [GB/GB]; c/o Pharmagene Laboratories Limited, 2 Orchard Road, Royston Hertfordshire

SG8 5HD (GB). **DAVIS, Richard,** Jon [GB/GB]; c/o Pharmagene Laboratories Limited, 2 Orchard Road, Royston Hertfordshire SG8 5HD (GB). **COLEMAN, Robert,** Alexander [GB/GB]; c/o Pharmagene Laboratories Limited, 2 Orchard Road, Royston Hertfordshire SG8 5HD (GB). **CLARK, Kenneth,** Lyle [GB/GB]; c/o Pharmagene Laboratories Limited, 2 Orchard Road, Royston Hertfordshire SG8 5HD (GB).

(74) Agents: **WATSON, Robert** et al.; Mewburn Ellis LLP, York House, 23 Kingsway, London Greater London WC2B 6HP (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,

[Continued on next page]


(54) Title: FURAN DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS



(I)



(II)



(III)

(57) Abstract: A compound of formula: (I); or a salt, solvate and chemically protected form thereof, wherein one of R² and R⁵ is: (i) H or an optionally substituted C₁₋₄ alkyl group; or (ii) an optionally substituted C₅₋₇ aryl; and the other of R² and R⁵ is the other group; m and n can be 0 or 1, and m + n = 1 or 2 R^N is H or optionally substituted C₁₋₄ alkyl R³ is either: (i) carboxy; (ii) a group of formula: (II); (iii) a group of formula: (III); wherein R is optionally substituted C₁₋₇ alkyl, C₅₋₂₀ aryl, or NR^{N3}R^{N4}, where R^{N3} and R^{N4} are independently selected from optionally substituted C₁₋₄ alkyl; or (iv) tetrazol-5-yl.



JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW. ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.